autologous plasma Report issue

Biological Experimental
AACT

Active Ingredient History

NOW
  • Now
Platelet-rich plasma (PRP), also known as autologous conditioned plasma, is a concentrate of platelet-rich plasma protein derived from whole blood, centrifuged to remove red blood cells. Though promoted to treat an array of medical problems, evidence for benefit is mixed as of 2020, with some evidence for use in certain conditions and against use in other conditions.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

autologous concentrated plasma | autologous conditioned plasma | autologous freeze dried plasma | autologous plasma

Organizations (28)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Hypovolemia

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Aging (Phase 1/Phase 2)

Bleeding Time (Phase 3)

COVID-19 (Phase 2/Phase 3)

Dry Eye Syndromes (Early Phase 1)

Healthy Volunteers (Phase 1)

Hemorrhage (Phase 3)

Lung Diseases (Phase 2/Phase 3)

Melanoma (Early Phase 1)

Osteoarthritis, Knee (Phase 2/Phase 3)

Respiratory Distress Syndrome (Phase 2/Phase 3)

Shock, Septic (Phase 2)

Spinal Diseases (Phase 3)

Thrombocytopenia (Phase 4)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue